Mucositis and non-invasive markers of small intestinal function.
Mucositis is a common and debilitating side effect of chemotherapy that manifests due to the inability of chemotherapy agents to discriminate between normal and neoplastic cells. This results in ulcerating lesions lining the gastrointestinal tract. Moreover, the development of efficacious treatments for small intestinal mucositis has been hindered as the pathobiology of mucositis is still not fully understood. The small intestine is an extensive organ which is largely inaccessible by conventional means. Non-invasive biomarkers such as small intestinal permeability, H(2) breath tests, serum citrulline tests and the (13)C-sucrose breath test (SBT) have emerged as potential markers of small intestinal function. The SBT is emerging as the more appropriate biomarker to assess chemotherapy-induced mucositis in cancer patients and animal models, where it measures the decrease in sucrase activity associated with villus blunting and crypt disruption. The SBT has been successfully applied to detect mucositis induced by different classes of chemotherapy agents and has been used successfully to monitor small intestinal function with a range of candidate anti-mucositis treatments. We propose the SBT a superior biomarker of small intestinal function that could be successfully applied in clinical practice for monitoring the development of mucositis in cancer patients undergoing chemotherapy.
Tooley
Katie L
KL
Centre for Paediatric and Adolescent Gastroenterology, Children, Youth and Women's Health Service and Discipline of Physiology, University of Adelaide, 72 King William Road, North Adelaide, SA, Australia. katie.inglis@adelaide.edu.au
Howarth
Gordon S
GS
Butler
Ross N
RN
D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D052016:Mucositis / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*
D015415:Biomarkers